An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call and webcast on April 28, 2022 at 8:30 a.m. ET to discuss its first quarter financial results. Domestic participants can dial (844) 413-7154, while international participants should call (216) 562-0466, using participant code 1068226. A replay will be available for 30 days on the company's website. GlycoMimetics specializes in glycobiology-based therapies for cancer and inflammatory diseases, focusing on small molecule drugs known as glycomimetics.
Positive
None.
Negative
None.
ROCKVILLE, Md.--(BUSINESS WIRE)--
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Thursday, April 28, 2022, at 8:30 a.m. ET.
The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1068226. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect.
A webcast replay will be available via the “Investors” tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, participant code 1068226.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
When will GlycoMimetics report its first quarter financial results?
GlycoMimetics will report its first quarter financial results on April 28, 2022, at 8:30 a.m. ET.
How can I listen to the GlycoMimetics conference call?
Participants can listen to the GlycoMimetics conference call by dialing (844) 413-7154 for domestic calls or (216) 562-0466 for international calls.
Is there a replay available for the GlycoMimetics conference call?
Yes, a webcast replay will be available on the GlycoMimetics website for 30 days after the call.
What is GlycoMimetics focused on developing?
GlycoMimetics is focused on discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia, and for inflammatory diseases.
